VolitionRx Limited (VNRX) Financial Ratios
22 years of historical data (2004–2025) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: 9.33
30Y Low4.7·High142.3
ROE
↓
N/A
—
5yr avg: -286.2%
30Y Low-490%·High-87%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
VNRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
VolitionRx Limited currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $12M | $27M | $52M | $51M | $135M | $165M | $176M | $186M | $57M | $78M | $105M |
| Enterprise Value | $22M | $38M | $54M | $36M | $129M | $149M | $161M | $173M | $47M | $70M | $85M |
| P/E Ratio → | -0.51 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.97 | 15.80 | 42.09 | 65.88 | 438.98 | 1836.39 | 13112.09 | 10863.06 | — | — | — |
| P/B Ratio | — | — | — | — | — | 9.33 | 10.81 | 13.08 | 4.68 | 7.79 | 4.97 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
VNRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 21.79 | 44.16 | 46.70 | 419.75 | 1652.42 | 11995.20 | 10100.98 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
VNRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
VolitionRx Limited earns an operating margin of -1228.6%. Operating margins have expanded from -4641.8% to -1228.6% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating Margin | -1228.6% | -1228.6% | -2190.9% | -4641.8% | -10372.4% | -31469.0% | -158176.2% | -93840.2% | — | — | — |
| Net Profit Margin | -1352.2% | -1352.2% | -2186.3% | -4555.5% | -9879.1% | -29782.5% | -151508.3% | -94168.5% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -414.8% | -157.7% | -133.5% | -122.2% | -163.0% | -94.9% | -87.5% |
| ROA | -286.6% | -286.6% | -144.4% | -152.7% | -132.2% | -100.0% | -85.8% | -83.0% | -112.2% | -75.1% | -73.4% |
| ROIC | — | — | — | — | — | -1735.8% | -1295.3% | -764.1% | -584.7% | -630.4% | -1245.4% |
| ROCE | — | — | -262.2% | -361.4% | -290.4% | -138.6% | -113.8% | -98.5% | -130.2% | -85.9% | -83.8% |
VNRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $10M ($11M total debt minus $1M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.23 | 0.27 | 0.28 | 0.27 | 0.28 | 0.07 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | -0.93 | -0.92 | -0.92 | -0.84 | -0.74 | -0.95 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.44 | -8.44 | -79.09 | -159.98 | -175.78 | -172.23 | -156.16 | -126.19 | -161.35 | -200.95 | — |
VNRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.17x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 2.44x to 0.17x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.17 | 0.17 | 0.52 | 2.44 | 0.70 | 3.37 | 3.26 | 4.55 | 5.96 | 4.61 | 10.82 |
| Quick Ratio | 0.17 | 0.17 | 0.52 | 2.44 | 0.70 | 3.28 | 3.26 | 4.55 | 5.96 | 4.61 | 10.82 |
| Cash Ratio | 0.09 | 0.09 | 0.42 | 2.32 | 0.63 | 3.16 | 3.12 | 4.40 | 5.75 | 4.42 | 10.66 |
| Asset Turnover | — | 0.25 | 0.13 | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 67.15 | 32.72 | 114.22 | 86.50 | 50.72 | 193.41 | — | — | — | — |
VNRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
VolitionRx Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $5M | $4M | $4M | $3M | $3M | $2M | $2M | $2M | $1M | $1M |
Peer Comparison
Compare VNRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VNRXYou | $12M | -0.5 | — | — | 100.0% | -1228.6% | — | — | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 ILMN | $22B | 26.0 | 20.0 | 23.1 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 NTRA | $28B | -127.8 | — | 252.3 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 GKOS | $8B | -40.7 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — |
 GH | $13B | -28.8 | — | — | 64.5% | -44.4% | — | -34.9% | — |
 CDNA | $1B | -54.5 | — | 31.2 | 67.0% | -5.5% | -6.3% | -5.7% | — |
 TMDX | $2B | 13.9 | 17.1 | 17.5 | 59.9% | 17.9% | 54.2% | 18.8% | 3.5 |
 BNGO | $14M | -0.3 | — | — | 49.4% | -116.9% | -66.2% | -49.1% | — |
 PRME | $580M | -2.4 | — | — | -58.1% | -4498.1% | -146.8% | -168.3% | — |
 TMO | $173B | 26.2 | 18.7 | 27.5 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 22 years · Updated daily
See VNRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VNRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VNRX vs EXAS
Side-by-side business, growth, and profitability comparison vs Exact Sciences Corporation.
Start ComparisonVNRX — Frequently Asked Questions
Quick answers to the most common questions about buying VNRX stock.
What is VolitionRx Limited's P/E ratio?
VolitionRx Limited's current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
Is VNRX stock overvalued?
Based on historical data, VolitionRx Limited is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are VolitionRx Limited's profit margins?
VolitionRx Limited has 100.0% gross margin and -1228.6% operating margin.